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Abstract: Differentiating between chronic obstructive pulmonary disease (COPD) patients with 
normal (PiMM) or deficient (PiZZ) genetic variants of alpha-1 antitrypsin (A1AT) is important not 
only for understanding the pathobiology of disease progression but also for improving personalized 
therapies. This pilot study aimed to investigate whether urinary peptides reflect the A1AT-related 
phenotypes of COPD. Urine samples from 19 clinically stable COPD cases (7 PiMM and 12 PiZZ 
A1AT) were analyzed by capillary electrophoresis coupled to mass spectrometry. We identified 
66 peptides (corresponding to 36 unique proteins) that differed between PiZZ and PiMM COPD. 
Among these, peptides from the collagen family were the most abundant and divergent. A logis-
tic regression model based on COL1A1 or COL5A3 peptides enabled differentiation between 
PiMM and PiZZ groups, with a sensitivity of 100% and specificity of 85.71% for COL1A1 
and a sensitivity of 91.67% and specificity of 85.71% for COL5A3. Furthermore, patients with 
PiZZ presented low levels of urinary peptides involved in lipoproteins/lipids and retinoic acid 
metabolism, such as apolipoprotein A-I and C4, retinol-binding protein 4 and prostaglandin-H2 
d-isomerase. However, peptides of MDS1 and EVII complex locus, gelsolin and hemoglobin 
alpha were found in the urine of COPD cases with PiZZ, but not with PiMM. These capillary 
electrophoresis coupled to mass spectrometry-based results provide the first evidence that urinary 
peptide content differs between PiMM and PiZZ patients with COPD.
Keywords: alpha-1 antitrypsin, alpha-1 antitrypsin deficiency, COPD, urine, peptidomics, capillary 
electrophoresis coupled to mass spectrometry, phenotypes, peptides, biomarkers, collagen
Introduction
Chronic obstructive pulmonary disease (COPD), characterized by the chronic and 
progressive obstruction of lung airflow,1 is the fourth leading cause of mortality 
and morbidity worldwide.2 COPD is a highly heterogeneous disorder resulting from 
gene–environment interactions. Even in patients with similar limitations in airflow, the 
clinical, physiologic and radiologic presentation of COPD can vary significantly from 
patient to patient. Therefore, to improve the management of COPD, it is important to 
identify clinically significant subgroups of COPD or “COPD phenotypes”.3 A fraction 
of patients with COPD has inherited PiZZ (Glu342Lys) alpha-1 antitrypsin deficiency 
(A1ATD), a major genetic determinant influencing the development of early-onset 
COPD with emphysema, especially in cigarette smokers.4 The identification of bio-
markers that can distinguish between A1ATD-PiZZ and non-A1ATD-PiMM COPD 
phenotypes could improve our understanding of the disease-driving mechanisms.
The use of proteomics is a growing trend in the search for new biomarkers of 
COPD. The advantage of this method is that it prompts various hypothesis-generating 
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models, but not necessarily hypothesis-driven results. Current 
proteomic screenings in patients with COPD have involved 
mostly samples from the respiratory system, including 
bronchoalveolar lavage fluid, lung tissue, epithelial lining 
fluid and induced sputum. Several studies have investigated 
potential protein biomarkers in plasma and serum,5 and 
proteomic analyses have implicated proteins involved in 
the regulation of inflammation, oxidative stress, immune 
responses and structural proteins.6–9
Urine is one of the frequently used biofluids in clinical 
studies because it is easy to obtain in large quantities and it 
contains proteins and peptides, which are quite stable and 
less complex than in plasma.10 For these reasons, urine is 
an excellent reservoir of biomarkers (peptides, proteins 
and metabolites) for many diseases.11 For example, the 
levels of elastin degradation products, such as desmosine/
isodesmosine, have been investigated in the urine of COPD 
patients with and without A1ATD.12 However, urinary des-
mosine levels are variable and raise during exacerbations 
of COPD, limiting the application of this measurement in a 
clinical setting.13,14
A novel approach for identifying urinary biomarkers 
employs capillary electrophoresis (CE) coupled to mass 
spectrometry (MS). Previously, this method was rarely used, 
owing to the limitations associated with coupling CE to the 
MS instrument and the restricted loading capacity of CE 
capillaries. However, the significantly increased sensitivity 
of modern MS and optimized methods for coupling CE to 
MS have transformed CE–MS into an appropriate tool for 
profiling disease-associated metabolites in body fluid samples 
such as urine. CE–MS enables simultaneous quantification 
of hundreds of peptides in a urine sample, which can then 
be incorporated into a diagnostic or prognostic score.15 This 
method has enabled the identification of urinary biomarker 
classifiers that are highly specific for the diagnosis of various 
human diseases.10,16,17 Therefore, we hypothesized that urinary 
peptidome analysis using CE–MS may help to identify specific 
peptide profiles in PiZZ and PiMM patients with COPD.
Materials and methods
Patients
Nineteen clinically stable patients with COPD (10 females and 
9 males; 16 ex-smokers and 3 never-smokers) were enrolled for 
urine analysis at the National Institute of Tuberculosis and Lung 
Diseases in Warsaw and at the Regional Centre of Pulmonology 
in Bydgoszcz. The Ethics Com mittee at the National Institute of 
Tuberculosis and Lung Diseases in Warsaw approved the study 
(KB-170/2011), and all subjects signed an informed consent 
form. Patients were subdivided according to their A1AT 
genotype: 7 with PiMM and 12 with PiZZ. Pulmonary func-
tion tests were performed according to the American Thoracic 
Society/European Respiratory Society criteria. Plasma levels of 
A1AT and other variables were analyzed at the clinical center 
in Warsaw.
Urine samples
Midstream morning urine was collected in sterile containers 
and stored at -80°C prior to analysis, as recommended by the 
European Kidney and Urine Proteomics and Human Kidney 
and Urine Proteome Project and described previously.18 For 
analysis, urine was diluted in a solution containing 2 M urea, 
10 mM NH
4
OH and 0.02% (w/v) sodium dodecyl sulfate. 
To remove higher molecular mass proteins, such as albumin 
and immunoglobulin G, each sample was ultrafiltered using 
a Centrisart ultracentrifugation filter device (20 kDa cutoff 
Vivaspin; Sartorius, Goettingen, Germany) at 3,000× g until 
1.1 mL of filtrate was obtained. To remove urea, electrolytes 
and salts and to enrich polypeptides, the filtrate was then 
applied to a PD-10 desalting column (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden) equilibrated with 0.01% 
NH
4
OH in high-performance liquid chromatography grade 
water (Roth, Bavaria, Germany). Finally, the samples were 
lyophilized and stored at 4°C. Shortly before CE–MS analy-
ses, the samples were dissolved in high-performance liquid 
chromatography grade water, as described elsewhere.19
Ce–Ms analyses
For analysis, the sample resuspension volume was adjusted 
to yield 0.8 μg/μL protein as measured by the BCA assay 
(Pierce Biotechnology, Rockford, IL, USA). CE–MS analy-
ses were performed using a CE system (Beckman Coulter, 
Fullerton, CA, USA) coupled to a micrOTOF II MS (Bruker 
Daltonic, Bremen, Germany) by Mosaiques Diagnostics 
GmbH (Hannover, Germany), and the analyses passed all 
quality control criteria. Validation experiments were per-
formed, and the reference signals of 1770 urinary polypep-
tides were used for CE–MS calibration.20 For normalization 
of the dilution variances, signal intensities were normalized 
to 29 housekeeping peptides.21 The obtained peaks indicated 
the molecular mass of each polypetide, the normalized CE 
migration (minutes) and the normalized signal intensities. 
Accuracy, precision, selectivity, sensitivity, reproducibility 
and stability of the CE–MS measurements were demonstrated 
elsewhere.22 All detected peptides were deposited, matched 
and annotated in a Microsoft SQL database to enable further 
statistical analyses.21 STATISTICA 8.0 (StatSoft Inc., Tulsa, 
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OK, USA) was used for the data calculations. Functional 
analysis was performed using Gene Group Functional Profil-
ing, g:Profiler (http://biit.cs.ut.ee/gprofiler/).23
Results
Patient characteristics
General patient characteristics are summarized in Table 1. 
Our cohort included patients having different severity of 
COPD: five PiZZ cases and one PiMM case were categorized 
as very severe (forced expiratory volume in 1 second 
[FEV
1
] ,35%), seven PiZZ and five PiMM cases as severe 
(35%, FEV
1
,49%) and one PiMM case as moderate 
(50%, FEV
1
,79%). As expected, the patients with PiZZ 
were younger than those with PiMM (mean [standard 
deviation {SD}]: 54.67±9.03 vs 65.71±6.27 years, respec-
tively, P,0.05) and had lower plasma levels of A1AT (mean 
[SD]: PiZZ 22.52±5.43 mg/dL vs PiMM 166.29±22.89 mg/dL, 
P,0.0001). The patient groups did not differ statistically in 
terms of the pulmonary function tests, anthropometric mea-
sures and other serum parameters (Table 1).
Functional clustering analysis
We identified over 4200 peptides in each urine sample; how-
ever, only 66 peptides (corresponding to 36 unique proteins) 
differed between the PiMM and PiZZ COPD cases. We used 
the web server g:Profiler to predict the function of 36 proteins 
(http://biit.cs.ut.ee/gprofiler/).23 Functional analysis revealed 
that the differentially expressed peptides were clustered 
in significant gene ontology categories related to biologic 
processes, cellular components, molecular functions and 
biologic pathways. As shown in Table 2, most of the peptides 
are related to the regulation of immune processes, collagen 
catabolism and biosynthesis, endoplasmic reticulum, protein 
digestion, the PI3K-Akt pathway and scavenging by class A 
receptor, among others.
Urinary peptides distinguish PiZZ and 
PiMM COPD cases
Urinary peptides from the collagen family were the most 
abundant and divergent in our patient cohort. Specifi-
cally, COL4A5, COL5A3, COL7A1, COL8A2, COL9A3, 
COL11A1 and COL23A1 were more frequent in the COPD 
cases with PiMM, whereas COL4A1 and COL4A3 were 
more frequent in the COPD cases with PiZZ. Further analysis 
revealed that COL1A1 (number 15, Table 3; 100% sensitiv-
ity, 85.71% specificity, P,0.005) and both COL5A3 and 
COL3A1 (numbers 52 and 62, Table 3; 91.67% sensitivity, 
85.71% specificity, P,0.005) were useful for discriminating 
between the PiZZ and PiMM groups.
Interestingly, cases with PiZZ COPD presented low 
levels of urinary peptides involved in lipoproteins/lipids 
and retinoic acid metabolism, such as apolipoprotein A-I 
and C4, retinol-binding protein 4 and prostaglandin-H2 
d-isomerase. In particular, peptides of apolipoprotein C4 
(number 60, Table 3) discriminated PiZZ from PiMM cases 
with a sensitivity of 91.67% and a specificity of 85.71% 
(P,0.005). However, peptides of MDS1 and EVII complex 
locus, gelsolin and hemoglobin alpha, were found in the urine 
of PiZZ, but not PiMM cases (Table 3). We identified two 
Table 1 Characteristics of COPD patients
Variables A1AT genotype Mann–Whitney test
PiZZ 
(n=12)
PiMM 
(n=7)
P-value Z-adjusted
Age (years) 54.7 (9) 65.7 (6.3) 1.21e-02 -2.51
gender, M/F 5/7 4/3
Smoking history, 
never/ex-smokers
1/11 2/5
Pack-years 19.2 (11) 32.9 (26) ns -1.84
FeV1% 37.6 (13.8) 43.7 (11.2) ns -0.63
FeV1 (l) 1.1 (0.4) 1.1 (0.6) ns 0.08
FeV1%/FVC 37 (10.2) 47.3 (12.5) ns -1.14
FVC (l) 3 (0.9) 2.5 (1.2) ns 0.78
FVC% 78.1 (15.8) 77.5 (12.7) ns 0.21
VC (l) 3.2 (0.8) 1.4 (0.3) 4.13e-02 2.04
VC% 84.8 (14.8) 75.4 (16.1) ns 0.75
PeF (l) 3.1 (0.8) 1.8 (0.3) ns 1.83
PeF% 41.8 (11.4) 38.5 (6.5) ns 0.43
A1AT (mg/dL) 22.5 (5.4) 166.3 (22.9) 4.53e-04 -3.51
hsCRP (mg/dL) 0.8 (1.4) 0.9 (0.7) ns -0.47
alT (U/l) 28.8 (14.9) 17.6 (3.3) ns 1.77
asT (U/l) 26.5 (9) 19 (3) ns 0.94
leukocytosis (109/l) 9.5 (3.5) 8.1 (1.5) ns 0.49
neutrophils (109/l) 6.1 (2.7) 5.6 (2.1) ns 0.14
neutrophils (%) 63 (6.4) 60.8 (5.2) ns 0.64
lymphocytes (109/l) 2.3 (0.5) 2.5 (0.6) ns -0.49
lymphocytes % 26.2 (7.8) 28.3 (3.5) ns -0.21
Monocytes (109/l) 0.8 (0.5) 0.8 (0.1) ns -1.34
Monocytes % 8.1 (2.5) 9.6 (1.1) ns -0.78
eosinophils (109/l) 0.3 (0.4) 0.1 (0.1) ns 1.01
eosinophils % 2.8 (3.3) 1.1 (0.8) ns 0.93
pO2 (Torr) 60.3 (8.5) 52.9 (11.4) ns 0.85
pCO2 (Torr) 38.2 (7) 43.8 (6.3) ns -0.76
sO2 % 91.6 (3.5) 86.3 (5.4) ns 1.04
ph 7.5 (0.03) 7.4 (0.03) ns 1.43
hCO3
- (mmol/l) 25.6 (3.7) 27.1 (2.8) ns -0.66
Be (mmol/l) 1.7 (3.4) 2.6 (2.6) ns -0.66
Note: all data are presented as mean (standard deviation). 
Abbreviations: a1aT, α1-antitrypsin; alT, alanine transaminase; asT, aspartate 
transaminase; BE, base excess/deficit; ECM, extracellular matrix; FEV1, forced 
expiratory volume in 1 second; FVC, forced vital capacity; hCO3, hydrogen 
carbonate; hsCRP, high-sensitive C-reactive protein; pCO2, partial pressure of 
carbon dioxide; PEF, peak expiratory flow; pO2, partial pressure of oxygen; SO2, 
oxygen saturation; VC, vital capacity.
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Table 2 The 36 proteins functionally clustered by g:Profiler
Biologic process Count P-value Genes
Collagen catabolic process 11 4e-16 COL11A1, COL5A3, COL1A1, COL7A1, COL2A1, COL1A2, 
COL3A1, COL4A3, COL8A2, COL4A1, COL4A5
ECM organization 13 2e-11 COL11A1, COL5A3, COL9A3, COL1A1, COL7A1, COL2A1, GSN, 
COL1A2, COL3A1, COL4A3, COL8A2, COL4A1, COL4A5
Collagen fibril organization 6 1e-07 COL11A1, COL5A3, COL1A1, COL2A1, COL1A2, COL3A1
Anatomic structure morphogenesis 17 4e-04 COL11A1, COL1A1, COL7A1, APOA1, ANXA1, RBP4, COL2A1, 
GSN, RUNX1, MYL3, COL1A2, COL3A1, COL4A3, KRT13, 
COL8A2, BCL9L, COL4A1
Collagen-activated tyrosine kinase 
receptor signaling pathway
3 5e-04 COL4A3, COL4A1, COL4A5
Animal organ development 19 5e-04 COL11A1, COL5A3, COL9A3, COL1A1, APOA1, ANXA1, RBP4, 
COL2A1, RUNX1, MYL3, COL1A2, B2M, COL3A1, COL4A3, 
KRT13, COL8A2, BCL9L, KRT10, COL4A1
Circulatory system development 11 1e-03 COL11A1, COL1A1, RBP4, COL2A1, RUNX1, MYL3, COL1A2, 
COL3A1, COL4A3, COL8A2, COL4A1
Cellular response to amino acid stimulus 4 8e-03 COL1A1, COL1A2, COL3A1, COL4A1
sensory perception of sound 5 1e-02 COL11A1, COL1A1, COL2A1, COL4A3, ESPN
Tissue development 13 2e-02 COL11A1, COL1A1, COL7A1, ANXA1, RBP4, COL2A1, GSN, 
RUNX1, MYL3, COL3A1, BCL9L, KRT10, COL4A1
receptor-mediated endocytosis 6 2e-02 UNC119, APOA1, SNX9, B2M, HBA1, HBB
Response to wounding 8 4e-02 COL1A1, APOA1, ANXA1, GSN, COL1A2, COL3A1, SERPINA1, 
HBB
Regulation of immune system process 11 5e-02 COL1A1, APOA1, IRAK2, ANXA1, RBP4, COL2A1, GSN, RUNX1, 
COL1A2, B2M, COL3A1
Cellular component
endoplasmic reticulum lumen 16 9e-20 COL23A1, COL11A1, COL5A3, COL9A3, COL1A1, COL7A1, 
APOA1, COL2A1, COL1A2, B2M, COL3A1, COL4A3, COL8A2, 
COL4A1, COL4A5, SERPINA1
Complex of collagen trimers 10 3e-19 COL11A1, COL5A3, COL1A1, COL7A1, COL2A1, COL1A2, 
COL3A1, COL4A3, COL4A1, COL4A5
endocytic vesicle lumen 3 9e-03 APOA1, HBA1, HBB
Vesicle 19 2e-02 COL5A3, CHGB, PTGDS, COL1A1, COL7A1, APOA1, SNX9, 
IRAK2, ANXA1, FXYD2, RBP4, GSN, COL1A2, B2M, KRT13, 
KRT10, SERPINA1, HBA1, HBB
Molecular function
eCM structural constituent 11 2e-15 COL11A1, COL5A3, COL9A3, COL1A1, COL2A1, COL1A2, 
COL3A1, COL4A3, COL8A2, COL4A1, COL4A5
Platelet-derived growth factor binding 5 2e-08 COL1A1, COL2A1, COL1A2, COL3A1, COL4A1
Haptoglobin binding 2 2e-02 HBA1, HBB
Biologic pathway (KEGG)
Protein digestion and absorption 12 5e-16 COL11A1, COL5A3, COL9A3, COL1A1, COL7A1, FXYD2, 
COL2A1, COL1A2, COL3A1, COL4A3, COL4A1, COL4A5
eCM–receptor interaction 7 2e-07 COL9A3, COL1A1, COL2A1, COL1A2, COL4A3, COL4A1, COL4A5
amebiasis 6 3e-05 COL1A1, COL1A2, COL3A1, COL4A3, COL4A1, COL4A5
AGE–RAGE signaling pathway in 
diabetic complications
6 3e-05 COL1A1, COL1A2, COL3A1, COL4A3, COL4A1, COL4A5
Focal adhesion 7 1e-04 COL9A3, COL1A1, COL2A1, COL1A2, COL4A3, COL4A1, COL4A5
PI3K/Akt signaling pathway 7 4e-03 COL9A3, COL1A1, COL2A1, COL1A2, COL4A3, COL4A1, COL4A5
african trypanosomiasis 3 8e-03 APOA1, HBA1, HBB
Biologic pathway (reactome)
Collagen biosynthesis and modifying 
enzymes
13 7e-19 COL23A1, COL11A1, COL5A3, COL9A3, COL1A1, COL7A1, 
COL2A1, COL1A2, COL3A1, COL4A3, COL8A2, COL4A1, COL4A5
Scavenging by Class A receptors 5 6e-07 COL1A1, APOA1, COL1A2, COL3A1, COL4A1
nCaM1 interactions 4 1e-03 COL9A3, COL4A3, COL4A1, COL4A5
Abbreviations: RAGE, receptor for advanced glycation endproduct; AGE, advanced glycation endproduct; NCAM1, neural cell adhesion molecule 1; KEGG, Kyoto 
encyclopedia of genes and genomes; eCM, extracellular matrix.
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Table 3 Urinary peptides distinguish PiZZ and PiMM COPD cases
Pep Protein name UniProt 
AC
Exp 
Mass
Peptide sequence Intensity, mean (SD) Z-adjusted FDR
PiZZ PiMM
 1 Hemoglobin subunit β P68871 2,659 FesFgDlsTPDaVMgnPKVKahgKK 148 (191) 519 (379) 2.1* 2e-03
 2 β-2-Microglobulin P61769 1,077 IVKWDrDM 16 (37) 127 (121) 2.9** 2e-03
 3 MDs1 and eVIl complex locus 
protein MDs1
Q13465 1,140 TshsssnVWh 3,724 (4,315) 0 (0) -2.6** 3e-03
 4 Collagen α-1(I) chain P02452 1,900 sPgrDgsPgaKgDrgeTgPa 12 (41) 259 (261) 2.5* 1e-03
 5 Collagen α-1(III) chain P02461 1,354 KgePggPgaDgVPgK 592 (389) 1,100 (551) 2* 8e-03
 6 Collagen α-1(III) chain P02461 2,154 ngePggKgergaPgeKgeggPPg 92 (142) 205 (82) 2.1* 3e-03
 7 Retinol-binding protein 4 P02753 1,439 lQKgnDDhWIVD 242 (623) 390 (243) 2.2* 5e-03
 8 Collagen α-1(I) chain P02452 1,355 gQPgaKgePgDagaK 46 (43) 108 (69) 2* 8e-03
 9 Collagen α-l(I) chain P02452 1,877 DDgeagKPgrPgergPPgP 1,985 (715) 3,634 (1,405) 2.1* 3e-03
10 gelsolin P06396 2,232 DeelggTPVQsrVVQgKePah 120 (176) 0 (0) -2.2* 2e-03
11 Hemoglobin subunit α P69905 2,021 aahlPaeFTPaVhaslDKF 21 (25) 0 (0) -2.2* 3e-03
12 Keratin; type I cytoskeletal 13 PI3646 1,361 eKITMQnlnDr 214 (464) 389 (246) 2* 9e-03
13 apolipoprotein a-I P02647 1,524 saleeYTKKlnTQ 0 (0) 179 (425) 2.4* 2e-03
14 Ig λ-2 chain C regions P0Cg05 3,202 WKaDssPVKagVeTTTPs 
KQsnnKYaassY
44 (125) 98 (66) 2.5* 6e-04
15 Collagen α-1(I) chain P02452 858 sPgeagrPg 410 (227) 134 (130) -3** 1e-02
16 Collagen α-1(VII) chain Q02388 2,410 glKgDrgDPgPQgPPglalgergPP 60 (200) 111 (113) 2* 3e-03
17 Prostaglandin-H2 d-isomerase P41222 1,843 YsQgsKgPgeDFrMaTl 20 (40) 61 (63) 2.2* 3e-03
18 annexin al P04083 2,057 FIeneeQeYVQTVKssK 0 (0) 34 (62) 2.4* 1e-03
19 α-1-antitrypsin P01009 1,943 eaIPMsIPPeVKFnKPFV 0 (0) 16,167 (39,363) 2.4* 1e-03
20 Myosin light chain 3 P08590 1,739 PaPaPPPePerPKeVe 362 (216) 587 (265) 2* 4e-03
21 α-1-antitrypsin P01009 2,042 eaIPMsIPPeVKFnKPFV 0 (0) 9,238 (22,506) 2.4* 1e-03
22 Collagen α-1(II) chain P02458 2,133 gargPegaQgPrgePgTPgsPgP 1,152 (687) 2,266 (1,111) 2.1* 3e-03
23 Collagen α-2(I) chain P08123 1,226 gPPgPDgnKgePg 539 (73) 690 (176) 2.2* 8e-03
24 Collagen α-1(I) chain P02452 1,211 sPgPDgKTgPPgP 0 (0) 94 (179) 2.4* 5e-03
25 Collagen α-l(I) chain P02452 1,408 gPPgeagKPgeQgVP 149 (287) 353 (339) 2.1* 7e-03
26 Hemoglobin subunit β P68871 2,171 TPeeKsaVTalWgK VnVDeV 0 (0) 341 (469) 2.8** 3e-04
27 Collagen α-l(I) chain P02452 2,150 DgQPgaKgePgDagaKgDagPPgP 1,774 (913) 3,022 (1,085) 2.6** 7e-04
28 Collagen α-2(I) chain P08123 1,171 DQgPVgrTgeVg 54 (113) 0 (0) -2.2* 1e-02
29 Collagen α-1(III) chain P02461 1,423 glPgTggPPgengKPg 2,341 (1,410) 3,863 (1,416) 2* 7e-03
30 Collagen α-1(I) chain P02452 2,584 agPPgaDgQPgaKgePg 
DagaKgDagPPgP
4 (13) 41 (61) 2.2* 2e-03
31 Collagen α-1(II) chain P02458 1,096 aPgeDgrPgPP 0 (0) 12 (18) 2.4* 8e-03
32 sodium/potassium-
transporting ATPase subunit γ
P54710 1,431 lsMDgggsPKgDVDP 56 (90) 169 (138) 2* 8e-03
33 Collagen α-1(III) chain P02461 1,660 gPPgPPgTsghPgsPgsPg 202 (228) 714 (282) 3** 3e-04
34 Collagen α-3(IV) chain Q01955 1,628 PgPPgPPgPPghPgPQgP 205 (124) 71 (95) -2* 6e-03
35 Collagen α-1(IV) chain P02462 1,717 gPPgPPgPPgPPgeKgQM 127 (412) 50 (47) 2.1* 4e-03
36 Collagen α-1(XXIII) chain Q86Y22 1,601 DPgPPgQsgrDgYPgP 49 (60) 189 (104) 2.3* 3e-03
37 Collagen α-3(IX) chain Q14050 3,048 QgDrgDKgaagaglDg 
PegDQgPQgPQgVPgTs
33 (67) 169 (146) 2.3* 1e-03
38 sodium/potassium-
transporting ATPase subunit γ
P54710 1,504 glsMDgggsPKgDVDP 0 (0) 42 (49) 2.4* 2e-03
39 Collagen α-5(IV) chain P29400 1,627 PgaPgFPgsKgePgDIl 101 (177) 460 (502) 2* 5e-03
40 Collagen α-1(XI) chain P12107 1,734 PPgPKgnMgPQgePgPPg 0 (0) 62 (69) 3.3** 1e-04
41 Collagen α-1(I) chain P02452 2,946 nsgePgaPgsKgDTgaKg 
ePgPVgVQgPPgPag
4 (8) 31 (34) 2.2* 2e-03
42 Collagen α-1(XI) chain P12107 1,675 KgengDVgPMgPPgPPgP 28 (39) 215 (185) 2.1* 4e-03
43 Collagen α-2(VIII) chain P25067 1,822 gPPgegragePgTagPTgPP 314 (378) 848 (304) 2.5* 1e-03
44 Collagen α-1 chain P02461 1,652 QPgeKgsPgaQgPPgaPg 4 (10) 79 (57) 3.1** 2e-04
45 Prostaglandin-H2 d-isomerase P41222 1,805 aQVsVQPnFQQDKFlg 0 (0) 32 (46) 2.4* 2e-03
46 Secretogranin-1 P05060 3,202 ssQggslPseeKghPQees 
eesnVsMaslge
43 (68) 220 (192) 2.3* 1e-03
(Continued)
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Table 3 (Continued)
Pep Protein name UniProt 
AC
Exp 
Mass
Peptide sequence Intensity, mean (SD) Z-adjusted FDR
PiZZ PiMM
47 Collagen α-2(I) chain P08123 1,853 ngaPgeagrDgnPgnDgPPg 118 (128) 13 (26) -2.2* 2e-03
48 Collagen α-1(III) chain P02461 1,860 nPgPPgPsgsPgKDgPPgPag 282 (201) 81 (101) -2.5* 1e-03
49 Collagen α-1(II) chain P02458 3,458 TgPPgPagFagPPgaDgQP 
gaKgeQgeagQKgDagaPgP
23,598 (6,494) 11,915 (9,047) -2.3* 1e-03
50 Collagen α-1(I) chain P02452 1,685 ePgsPgengaPgQMgPr 0 (0) 395 (953) 2.4* 2e-03
51 Collagen α-1(I) chain P02452 1,826 gangaPgnDgaKgDagaPgaPg 493 (414) 130 (126) -2.1* 3e-03
52 Collagen α-3(V) chain P25940 1,699 gIDgsPgeKgDPgDVggPg 1 (4) 39 (33) 3.4*** 8e-05
53 Keratin; type I cytoskeletal 10 P13645 1,737 TQllnnMrsQYeQl 0 (0) 244 (431) 2.8** 5e-04
54 Collagen α-(I) chain P02452 1,762 QgPggPPgPKgnsgePgaPg 0 (0) 34 (57) 2.4* 2e-03
55 runt-related transcription 
factor 1
Q01196 3,443 sIsDPrMhYPgaFTYsP 
TPVTsgIgIgMsaMgsa
3 (9) 81 (74) 2.9** 2e-04
56 Collagen α-1(I) chain P02452 2,104 gPPgeagKPgeQgVPgDlgaPgP 1,631 (447) 2,430 (662) 2.6** 7e-04
57 Interleukin-1 receptor-
associated kinase-like 2
O43187 2,192 angslQDrlQgQggsDPlPWP 2 (5) 15 (15) 2.1* 3e-03
58 Collagen α-2(I) chain P08123 3,633 DQgPVgrTgeVgaVg 
PPgFageKgPsgeagTagPPgTPgP
10 (32) 132 (105) 3.2** 7e-05
59 Sorting nexin-9 Q9Y5X1 2,501 asTaQasssaasnnhQ 
VgsgnDPWsa
19 (28) 107 (104) 2.2* 2e-03
60 apolip oprotein C-IV P55056 2,418 TQQPQQDeMPsPTFlTQVKes 8 (20) 67 (32) 3.3*** 6e-05
61 Collagen α-5(IV) chain P29400 2,646 gQDgIPgPagQKgePg 
QPgFgnPgPPgl
0 (0) 25 (47) 2.4* 1e-03
62 Collagen α-1(III) chain P02461 2,854 PQgPPgPTgPggDKgD 
TgPPgPQglQglPgT
2,570 (2,224) 8,157 (6,403) 2.5* 7e-04
63 espin B1aK53 1,005 lPPPPPPPPP 17 (19) 62 (51) 2* 3e-02
64 Collagen α-1(II) chain P02458 1,594 PgTPgnPgPPgPPgPPgP 110 (187) 8 (21) -2.2* 4e-03
65 Protein unc-119 homolog A Q13432 1,247 sesgsesePDagP 2 (6) 23 (35) 2.2* 6e-03
66 B-cell Cll/lymphoma 9-like 
protein
Q86UU0 1,557 PgMgWTeDlPPMggP 888 (431) 443 (255) -2.1* 5e-03
Notes: statistical results based on Mann–Whitney U-test and FDr test; exp Mass (molecular mass of the peptide, kDa), the Z-adjusted reported the equivalent P-values as 
follows: *P,0.05; **P,0.01; ***P.0.001.
Abbreviations: Cll, chronic lymphocytic leukemia; FDr, false discovery rate; sD, standard deviation.
peptides of A1AT in the urine of 43% of PiMM cases, but 
they were absent in PiZZ cases.
Discussion
The increased proteolytic activity and protease–antiprotease 
imbalance in COPD have been well described. Therefore, 
many studies have focused on identifying protease-generated 
peptides in various biologic fluids from patients with 
COPD.24 Recently, Wendt et al have used liquid chromatog-
raphy coupled to MS for metabolomic profiling of bronchial 
lavage fluid obtained from patients with COPD and further 
confirmed a significant increase in peptides compared with 
healthy controls.25
PiZZ A1ATD-related COPD is associated with low 
circulating levels of A1AT (10%–15% of normal levels), 
which is the main inhibitor of neutrophil proteases. Neu-
trophils are among the key participants in COPD, and they 
secrete serine proteases (neutrophil elastase, cathepsin G and 
proteinase-3) and matrix metalloproteinase (MMP)-8 and 
MMP-9.26,27 Active elastase can degrade many extracellular 
matrix substances, including elastin, collagen types I–IV and 
fibronectin, and activate MMPs.28 For example, it has been 
demonstrated that elastase, cathepsin G and proteinase-3 
activate MMP-2, and this activation is blocked by A1AT, 
but not by an MMP-inhibitor.29 Macrophages also secrete 
proteases, including MMP-2, MMP-9 and MMP-12, and 
cathepsins K, L and S. Macrophages from patients with 
COPD exhibit greater activation and elastolytic activity that 
those from non-COPD controls.28 Careful examination of 
the data revealed that A1AT deficiency favors proteolysis 
and tissue destruction, in general. Therefore, patients with 
COPD who carry inherited PiZZ A1ATD are expected 
to display higher levels of activated proteolytic enzymes 
and proteolysis-generated peptides than those with PiMM 
A1AT. Previous analyses of patients with COPD revealed 
that the protease caspase-9 is upregulated in the lung tissue 
of patients with PiZZ, whereas cathepsin B is upregulated 
in those with PiMM. Moreover, the differences between 
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PiZZ and PiMM COPD cases were found in processes 
related to protein biosynthesis, energy pathways and cellular 
defense response.30
COPD is associated with systemic abnormalities, such as 
renal and hormonal abnormalities, malnutrition, muscle wast-
ing, osteoporosis and others. These systemic abnormalities 
have been attributed to increased systemic inflammation. 
Therefore, COPD is considered to have a significant systemic 
component.31 Urine is a rich source of biomarkers for a wide 
range of systemic diseases; therefore, we hypothesized that 
urinary peptide profiles might differ in patients with PiZZ 
and PiMM COPD. This is the first study to apply CS–MS 
for the analysis of urinary peptides in PiMM and PiZZ 
COPD patients.
Using CS–MS to analyze urine from patients with COPD, 
we detected 66 urinary peptides (corresponding to 36 unique 
proteins) that differed between PiMM and PiZZ cases with 
COPD. The peptides related to collagen breakdown products, 
actin organization/vesicle trafficking, lipid metabolism and 
the PI3K/Akt pathway are interesting candidates for distin-
guishing COPD with and without inherited A1ATD.
Remarkably, peptides of the MDS1 and EVI1 complex 
locus protein MDS1, collagen α-2(I) chain, gelsolin and 
hemoglobin subunit α, were detected in the urine of the PiZZ 
cases only, whereas peptides of apolipoprotein A-I, A1AT, 
collagen α-1(I) chain and hemoglobin subunit β, were detected 
in the urine of the PiMM cases (Table 3). Gelsolin, an actin-
binding protein, is a key regulator of actin filament assembly. 
Caspase-3-mediated gelsolin fragmentation has been proposed 
to be an apoptotic effector mechanism in COPD pathogen-
esis and a marker of lung injury.32 Alterations in gelsolin 
expression have been associated with cigarette smoking and 
different pulmonary diseases such as fibrosis; however, little 
is known about the role of gelsolin in COPD.32–34 Gelsolin 
activates PI3K/Akt pathway,35 which regulates cell growth, 
proliferation, adhesion, migration and survival. Interestingly, 
it promotes the differentiation of alveolar epithelial type I and 
II cells from alveolar epithelial stem cells.36,37
COPD cases with PiZZ A1ATD presented low or unde-
tectable levels of peptides associated with lipoproteins/
lipids and retinoic acid metabolism, such as apolipoprotein 
A-I and C4, retinol-binding protein 4 and prostaglandin-H2 
d-isomerase. Apolipoprotein A-I is the main component 
of high-density lipoproteins. Moreover, it has a protective 
role as an antioxidative, anti-inflammatory and antiapop-
totic factor and as an inhibitor of metalloprotease activa-
tion in human lungs and cigarette smoke-exposed murine 
models.38–40 In addition, reduced levels of apolipoprotein 
A-I are observed in the lungs of patients with COPD, 
compared with smoker controls.38 Apolipoprotein A-I and 
retinol-binding protein 4 are proposed to be putative bio-
markers of COPD severity.41,42
A recent review by Bidan et al43 summarized various studies 
on lung collagen content in COPD. Despite the fact that many 
studies have found increased collagen in the lungs of patients 
with COPD, there are contrasting data about the contribution 
of individual collagen subtypes. Little is known about the 
collagen content in urine from patients with COPD.
We identified two peptides of A1AT that were present 
in the urine of 43% of the PiMM cases, but in none of the 
PiZZ cases. A1AT and its fragments have been reported to be 
upregulated in chronic kidney diseases.44–46 Peptides of A1AT 
were detected in the urine of patients with kidney diseases and 
sepsis, and were suggested as putative biomarkers.47 Thus, 
increased urinary excretion of fragments of A1AT may reflect 
chronic renal damage in some COPD cases with PiMM. Fur-
ther studies are required to investigate this possibility.
Due to the close relationship between the kidneys and 
urine, most current studies use the CE–MS method of iden-
tifying urinary biomarkers in the investigation of kidney 
diseases.48 However, only a limited number of urinary 
biomarker studies in lung diseases have been conducted, 
likely because the lung and the kidneys are not anatomi-
cally related, raising questions about the potential pres-
ence of lung disease biomarkers in urine. For example, 
enzyme-linked immunosorbent assay-based results 
from a recent study by Cane et al suggest that MMP 
levels in lung, serum and urine are independent of 
each other and do not reflect disease severity.49
CE–MS technology has certain limitations, as described 
in our previous publication.18 The small sample volume 
(,200 μL) and inability to determine the sequence of some 
of the biomarker peptides are among the most relevant limita-
tions. However, the advantages of this technology include its 
robustness, reproducibility and well-characterized platform, 
resulting in the availability of a database containing over 
40,000 highly comparable individual datasets.
Use of the CS–MS method, even in a small cohort, 
allowed detection of distinct patterns of urinary peptides 
differing between the PiZZ and PiMM patients with COPD. 
Our novel and preliminary data suggest a clinical value for 
urinary peptidomics and encourage further validation of the 
CS–MS method in COPD patient cohorts of sufficient size 
for appropriate power analysis.
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